idh1 mutant u87  (ATCC)

Journal: Inflammation Research

Article Title: IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression

doi: 10.1007/s00011-026-02223-8

Figure Lengend Snippet: The frequency of ILC1 is decreased, whereas ILC3 is increased, in IDH1-mutant human glioma tissues compared with the IDH1-wild-type group. A Representative flow-cytometry gating strategies for ILCs in human tonsil (control) tissue, IDH1-wildtype, and IDH1-mutant glioma tissue (FSC-A = forward-scatter area; SSC-A = side-scatter area). B Comparison of total ILC percentages in tonsil controls (n = 11), IDH1-wild-type (n = 9), and IDH1-mutant (n = 3) glioma tissues (top center); comparison of ILC1 percentages (bottom left), ILC2 percentages (bottom center), and ILC3 percentages (bottom right) across the same groups. C Comparison of mean fluorescence intensity (MFI) of KLRG1 (top left), PD-1 (top right), and CTLA-4 (bottom center) expression on ILC1s in tonsil control, IDH1-wild-type, and IDH1-mutant groups. D Comparison of MFI of KLRG1 (top left), PD-1 (top right), and CTLA-4 (bottom center) on ILC2s. E Comparison of MFI of KLRG1 (top left), PD-1 (top right), and CTLA-4 (bottom center) on ILC3s. Error bars represent ± SD. Statistical significance was determined by one-way ANOVA (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001)

Article Snippet: Human glioma U87-MG and its isogenic IDH1 (R132H)-mutant U87-MG (#HTB14IG) cell lines were obtained from the American Type Culture Collection (ATCC).

Techniques: Mutagenesis, Flow Cytometry, Control, Comparison, Fluorescence, Expressing

Journal: Inflammation Research

Article Title: IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression

doi: 10.1007/s00011-026-02223-8

Figure Lengend Snippet: The frequency of ILC3 is increased in the peripheral blood of IDH1-mutant glioma patients compared with the IDH1-wild-type group. A Representative flow-cytometry gating strategies for ILCs in peripheral blood of healthy controls, IDH1-wild-type glioma patients, and IDH1-mutant glioma patients (FSC-A = forward-scatter area; SSC-A = side-scatter area). B Comparison of total ILC percentages in blood samples from healthy controls (HC, n = 20), IDH1-wild-type (n = 12), and IDH1-mutant (n = 7) groups (top center); comparison of ILC1 (bottom left), ILC2 (bottom center), and ILC3 (bottom right) frequencies across the same groups. C Comparison of MFI of KLRG1 (top left), PD-1 (top right), and CTLA-4 (bottom center) on ILC1s in HC, IDH1-wild-type, and IDH1-mutant groups. D Comparison of MFI of KLRG1 (top left), PD-1 (top right), and CTLA-4 (bottom center) on ILC2s. E Comparison of MFI of KLRG1 (top left), PD-1 (top right), and CTLA-4 (bottom center) on ILC3s. Error bars represent ± SD. Statistical significance was determined by one-way ANOVA (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001)

Article Snippet: Human glioma U87-MG and its isogenic IDH1 (R132H)-mutant U87-MG (#HTB14IG) cell lines were obtained from the American Type Culture Collection (ATCC).

Techniques: Mutagenesis, Flow Cytometry, Comparison

Journal: Inflammation Research

Article Title: IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression

doi: 10.1007/s00011-026-02223-8

Figure Lengend Snippet: Co-culture of tonsil-derived ILCs with U87-MG significantly increased surface PD-1, KLRG1, and CTLA-4 compared with IDH1-mutant U87-MG. A – D Human tonsil-derived ILCs were cultured alone or co-cultured with U87-MG or IDH1-mutant U87-MG glioma cell lines, either with cytokine supplementation (recombinant human IL-2 [5 ng/mL], IL-7 [50 ng/mL], IL-12 [50 ng/mL], IL-1β [50 ng/mL], IL-23 [50 ng/mL]) or without cytokines for four days. Data points represent two independent experiments (ILC n = 3; U87-MG + ILC n = 6; IDH1-mutant U87-MG + ILC n = 6; technical replicates) A Representative flow-cytometry gating strategy for human tonsil-derived ILCs. B Flow-cytometry contour plots showing CTLA-4, KLRG1, and PD-1 surface expression percentages on ILCs. C Quantification of CTLA-4, KLRG1, and PD-1 expression percentages on ILCs. D Mean fluorescence intensity (MFI) of CTLA-4, KLRG1, and PD-1 expression on ILCs. E – F ILCs were cultured alone or exposed to glioma-conditioned medium (GCM) from U87-MG or IDH1-mutant U87-MG cell lines under the same cytokine conditions for four days. Data points represent two independent experiments (each with three technical replicates). E Percentages of CTLA-4, KLRG1, and PD-1–expressing ILCs following GCM exposure. F Corresponding MFI of CTLA-4, KLRG1, and PD-1 expression on ILCs. G – H Proliferation of CFSE-labeled tonsil ILCs co-cultured with U87-MG or IDH1-mutant U87-MG cells was analyzed after four days. G Representative flow-cytometry plots of CFSE dilution. H Quantification of proliferating CFSE-labeled ILCs from three independent experiments (each with four technical replicates). Error bars represent ± SD. Statistical analyses were performed using one-way ANOVA (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001)

Article Snippet: Human glioma U87-MG and its isogenic IDH1 (R132H)-mutant U87-MG (#HTB14IG) cell lines were obtained from the American Type Culture Collection (ATCC).

Techniques: Co-Culture Assay, Derivative Assay, Mutagenesis, Cell Culture, Recombinant, Flow Cytometry, Expressing, Fluorescence, Labeling

Journal: Inflammation Research

Article Title: IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression

doi: 10.1007/s00011-026-02223-8

Figure Lengend Snippet: IL-17 and IFN-γ production is increased in tonsil-derived ILCs exposed to glioma-conditioned medium (GCM) from U87-MG and IDH1-mutant U87-MG cell lines. A – E Tonsil-derived ILCs were cultured alone or with glioma-conditioned medium (GCM) obtained from U87-MG or IDH1-mutant U87-MG cell lines for four days, with or without cytokine supplementation (recombinant human IL-2 [5 ng/mL], IL-7 [50 ng/mL], IL-12 [50 ng/mL], IL-1β [50 ng/mL], IL-23 [50 ng/mL]). Golgi Stop was added during the final nine hours of incubation. A Percentages (left) and mean fluorescence intensity (MFI; right) of TNF-α–producing ILCs. B Percentages (left) and MFI (right) of IL-2–producing ILCs. C Percentages (left) and MFI (right) of IL-17–producing ILCs. D Percentages (left) and MFI (right) of IFN-γ–producing ILCs. E Percentages (left) and MFI (right) of GM-CSF–producing ILCs. Data represents two independent experiments (each with three technical replicates). Error bars indicate ± SEM. Statistical significance was determined by one-way ANOVA (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001)

Article Snippet: Human glioma U87-MG and its isogenic IDH1 (R132H)-mutant U87-MG (#HTB14IG) cell lines were obtained from the American Type Culture Collection (ATCC).

Techniques: Derivative Assay, Mutagenesis, Cell Culture, Recombinant, Incubation, Fluorescence

Journal: Inflammation Research

Article Title: IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression

doi: 10.1007/s00011-026-02223-8

Figure Lengend Snippet: D-2-HG levels are comparable in-patient plasma but elevated in glioma-conditioned medium (GCM) from IDH1-mutant U87-MG + ILC co-cultures compared with U87-MG + ILC. A Quantification of D-2-HG (OD₄₅₀) in plasma samples from healthy controls (HC, n = 12), IDH1-wild-type glioma patients (n = 12), and IDH1-mutant glioma patients (n = 7). B Quantification of D-2-HG (OD₄₅₀) in glioma-conditioned medium (GCM) collected from cultures of ILCs alone, U87-MG, IDH1-mutant U87-MG cell lines, and tonsil ILCs co-cultured with U87-MG or IDH1-mutant U87-MG cells under cytokine-supplemented (recombinant human IL-2 [5 ng/mL], IL-7 [50 ng/mL], IL-12 [50 ng/mL], IL-1β [50 ng/mL], IL-23 [50 ng/mL]) and cytokine-free conditions for four days. Data points represent two independent experiments (ILC n = 4, U87-MG + ILC n = 2, IDH1-mutant U87-MG + ILC n = 2 technical replicates). Error bars indicate ± SEM. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001)

Article Snippet: Human glioma U87-MG and its isogenic IDH1 (R132H)-mutant U87-MG (#HTB14IG) cell lines were obtained from the American Type Culture Collection (ATCC).

Techniques: Clinical Proteomics, Mutagenesis, Cell Culture, Recombinant

Journal: Molecular Imaging and Biology

Article Title: Autoradiography of Intracerebral Tumours in the Chick Embryo Model: A Feasibility Study Using Different PET Tracers

doi: 10.1007/s11307-025-01983-9

Figure Lengend Snippet: MR images of an EDD 19 chick embryo. A U87-MG tumour can be seen in the optic tectum (crosshair), presented in T2 ( A ) and T1 with ( B ) and without ( C ) contrast agent. Contrast agent enhancement is most profound in the tumour-rim region.

Article Snippet: U87 MG (ATCC® HTB-14TM) and U87 IDH1 R132H (ATCC® HTB-14IGTM) cells were cultured in Minimum Essential Medium Eagle containing 10% foetal calf serum, 1% L-glutamine, 1% MEM non-essential amino acids, and 1% penicillin/streptomycin, at 37 °C and 5% CO 2 .

Techniques:

Journal: Molecular Imaging and Biology

Article Title: Autoradiography of Intracerebral Tumours in the Chick Embryo Model: A Feasibility Study Using Different PET Tracers

doi: 10.1007/s11307-025-01983-9

Figure Lengend Snippet: Two representative EDD 19 chick embryo brains with U87-MG tumours showing a disrupted ( A,B ) and an intact ( C,D ) blood-tumour-barrier. A,C: 4’,6-diamidino-2-phenylindole (DAPI) staining shows densely packed tumour cells in the tectum opticum. B,D: Consecutive slices of A and C, respectively, with ( B ) and without ( D ) Evans blue dye extravasation in the tumour region, thus indicating a disrupted ( B ) and an intact ( D ) blood-tumour-barrier.

Article Snippet: U87 MG (ATCC® HTB-14TM) and U87 IDH1 R132H (ATCC® HTB-14IGTM) cells were cultured in Minimum Essential Medium Eagle containing 10% foetal calf serum, 1% L-glutamine, 1% MEM non-essential amino acids, and 1% penicillin/streptomycin, at 37 °C and 5% CO 2 .

Techniques: Staining

Journal: Molecular Imaging and Biology

Article Title: Autoradiography of Intracerebral Tumours in the Chick Embryo Model: A Feasibility Study Using Different PET Tracers

doi: 10.1007/s11307-025-01983-9

Figure Lengend Snippet: Consecutive 20 µm slices of an EDD 19 chick embryo brain with a U87-MG tumour using [ 18 F]FET. 4’,6-diamidino-2-phenylindole (DAPI) staining shows densely packed tumour cells in the ventricle and adjacent brain regions forming a solid tumour ( A ). The blood–brain barrier is disrupted within the tumour, as shown by Evans blue dye extravasation, especially in the tumour rim region ( B ). The corresponding [ 18 F]FET autoradiography shows a profound tracer accumulation in the tumour that is independent of the degree of blood–brain-barrier disruption ( C ). Astrocyte staining using an anti-GFAP antibody (Z0334, Dako) reveals astrocyte activation in the vicinity of the tumour ( D ).

Article Snippet: U87 MG (ATCC® HTB-14TM) and U87 IDH1 R132H (ATCC® HTB-14IGTM) cells were cultured in Minimum Essential Medium Eagle containing 10% foetal calf serum, 1% L-glutamine, 1% MEM non-essential amino acids, and 1% penicillin/streptomycin, at 37 °C and 5% CO 2 .

Techniques: Staining, Autoradiography, Disruption, Activation Assay

Journal: Molecular Imaging and Biology

Article Title: Autoradiography of Intracerebral Tumours in the Chick Embryo Model: A Feasibility Study Using Different PET Tracers

doi: 10.1007/s11307-025-01983-9

Figure Lengend Snippet: Consecutive 20 µm slices of an EDD 19 chick brain with a U87-IDH1 R132H tumour. 4’,6-diamidino-2-phenylindole (DAPI) staining shows densely packed tumour cells in both ventricles and adjacent brain regions that form two solid tumours ( A ). Ex vivo autoradiography with [ 18 F]FDOPA shows a profound tracer accumulation in the right tumour, while the left tumour visualises isometabolism ( B ). Immunostaining with a human nuclei marker (MAB1281, Merck Millipore) demonstrates the human origin of the tumours in red, whereas proliferating cells are visualised in green with the proliferation marker Ki-67 (ab16667, Abcam). All cell nuclei can be seen in blue ( C ). Detailed images of the border region of both the isometabolic left tumour ( D ) and hypermetabolic right tumour ( E ) are shown in higher magnification.

Article Snippet: U87 MG (ATCC® HTB-14TM) and U87 IDH1 R132H (ATCC® HTB-14IGTM) cells were cultured in Minimum Essential Medium Eagle containing 10% foetal calf serum, 1% L-glutamine, 1% MEM non-essential amino acids, and 1% penicillin/streptomycin, at 37 °C and 5% CO 2 .

Techniques: Staining, Ex Vivo, Autoradiography, Immunostaining, Marker

Journal: Molecular Imaging and Biology

Article Title: Autoradiography of Intracerebral Tumours in the Chick Embryo Model: A Feasibility Study Using Different PET Tracers

doi: 10.1007/s11307-025-01983-9

Figure Lengend Snippet: [ 68 Ga]FAPI-46 of a chick embryo on EDD 19. ( A ) 4’,6-diamidino-2-phenylindole (DAPI) image of U87 IDH1 R132H intracerebral tumour showing densely packed solid tumour cells in the ventricles ( B ) autoradiography of consecutive slice of A, showing profound tracer accumulation in the tumours.

Article Snippet: U87 MG (ATCC® HTB-14TM) and U87 IDH1 R132H (ATCC® HTB-14IGTM) cells were cultured in Minimum Essential Medium Eagle containing 10% foetal calf serum, 1% L-glutamine, 1% MEM non-essential amino acids, and 1% penicillin/streptomycin, at 37 °C and 5% CO 2 .

Techniques: Autoradiography